| Type | Title | Date Released | |
|---|---|---|---|
10-Q | Form 10-Q | ||
8-K | Harmony Biosciences Reports Q3 Financial Results, Strong WAKIX Sales and Positive BP-205 Orexin Agonist Data | ||
8-K/A | Form 8-K/A | ||
SCHEDULE 13G/A | BlackRock, Inc. (Filed by) | ||
8-K | Harmony Biosciences Announces Planned CEO Transition and Reaffirms 2026 Guidance | ||
4 | Budur Kumar (Reporting) | ||
144 | Form 144 | ||
144 | Form 144 | ||
144 | Form 144 | ||
4 | Budur Kumar (Reporting) | ||
144 | Form 144 | ||
144 | Form 144 |